HIV Latency Disruption via Selective Compound Formula I
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV treatments, such as HAART therapies, face challenges including drug resistance, inflammation-related morbidities, and incomplete elimination of viral reservoirs, necessitating the development of compounds with potency, limited cytotoxicity, and immune-modulation capabilities for effective HIV management.
Innovation Solution
A compound of the formula (I), where Y1 is a 5- or 6-membered aryl or heteroaryl optionally substituted with chloro, fluoro, oxo, and alkoxy groups, and R1 is C1-C6 alkylene, is developed, along with its pharmaceutical compositions and methods for treating, preventing, or curing HIV infection by administering the compound or its pharmaceutically acceptable salt.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HAART therapy is administered to suppress viral replication, then patient survival and quality of life are improved, but drug resistance emerges and inflammation-related morbidities increase
Solution Approach 1:
The invention segments the therapeutic approach by combining two distinct mechanisms: (1) antiretroviral drugs for viral replication suppression, and (2) compounds that selectively eliminate latently infected cells. This segmentation allows each component to address specific aspects of HIV management without the negative side effects of the other
Solution Approach 2:
The patent introduces compounds as intermediaries that bridge the gap between viral suppression and reservoir elimination. These compounds selectively target and eliminate latently infected cells through mechanisms that do not trigger widespread inflammation or resistance, acting as a mediator between the two therapeutic goals
2Reliability
If immune-modulators are used to reactivate latent reservoir, then viral reservoir elimination is achieved, but cytotoxicity increases
Solution Approach 1:
The invention applies local quality by designing compounds that selectively target only latently infected cells while sparing healthy cells. The compounds exhibit differentiated effects: they induce cell death specifically in HIV-latently infected cells through mechanisms such as disrupting latent virus production or enhancing immune recognition, while maintaining normal function in uninfected cells
Solution Approach 2:
The patent utilizes parameter changes by modifying cellular states rather than causing direct cytotoxic damage. The compounds change parameters such as viral production status, immune cell activation state, or cell surface marker expression, leading to selective elimination of infected cells through physiological processes rather than toxic mechanisms
3Reliability
If multiple drugs are combined in HAART regimen, then viral replication is suppressed, but treatment complexity and adherence difficulty increase
Solution Approach 1:
The invention merges multiple therapeutic functions into a single compound class. The described compounds simultaneously achieve: (1) elimination of latently infected cells, (2) suppression of active viral replication, and (3) modulation of immune response. This consolidation reduces the number of separate medications and dosing schedules patients must manage
Data Source
AI summary
The invention relates to compounds of Formula (I), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.